Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
US-guided Sciatic Nerve Block: Evaluation of the Intraneural Ropivacaine Minimal Effective Volume (MEV90)
NCT02589041Completed
- Sponsor
- ASST Gaetano Pini-CTO
- Start
- Nov 2015
- Primary completion
- Oct 2016
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Randomised, double-blind trial of ropivacaine in hallux valgus, sponsored by ASST Gaetano Pini-CTO. Primary endpoint: Minimal Effective Volume in 90% of patients at 6 months. Started Nov 2015; status: completed.
02
Drugs
ropivacaine
03
Conditions
hallux valgus
Beyond the preview
Go deeper on NCT02589041.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02589041.